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Abstract: Second generation antivenomics is a translational venomics approach designed to complement
in vivo preclinical neutralization assays. It provides qualitative and quantitative information on the
set of homologous and heterologous venom proteins presenting antivenom-recognized epitopes and
those exhibiting impaired immunoreactivity. In a situation of worrying antivenom shortage in many
tropical and sub-tropical regions with high snakebite mortality and morbidity rates, such knowledge
has the potential to facilitate the optimal deployment of currently existing antivenoms and to aid in the
rational design of novel broad specificity antidotes. The aim of the present work was to expand the
analytical capability of the immunoaffinity second-generation antivenomics platform, endowing it with
the ability to determine the maximal binding capacity of an antivenom toward the different toxins present
in a venom, and to quantify the fraction of venom-specific antibodies present in a given antivenom.
The application of this new platform, termed third generation (3G) antivenomics, in the preclinical
evaluation of antivenoms is illustrated in this paper for the case of antivenom EchiTAb-Plus-ICP®
reactivity towards the toxins of homologous (B. arietans) and heterologous (N. melanoleuca) venoms.
Keywords: snake venom; antivenom; preclinical assessment of antivenom; third generation
antivenomics; size-exclusion analysis of IgG-toxin complexes
1. Introduction
Snakebite envenoming is an occupational and environmental disease that annually kills over
95,000 people residing in some of the world’s most disadvantaged rural communities of tropical
and sub-tropical developing countries in sub-Saharan Africa, Asia, Latin America, and parts of
Oceania, and that leaves over 300,000 surviving victims with permanent physical disabilities [1–3].
The scale of this problem may be far greater than suggested by statistics from hospital-based care.
In addition to representing a significant cause of death, snakebite contributes to a depressing cycle
of poverty in the world’s most vulnerable communities [4,5]. Despite more than 45 commercial
or government antivenom producers existing around the world [6], the shortage of independently
validated, demonstrably safe, effective, and affordable snake antivenoms in many affected regions [7,8]
is an important contributor to this tropical disease burden [9]. To complicate matters, there is
growing evidence suggesting that some marketed antivenoms are clinically ineffective [10,11].
Although necessarily multicomponent in nature, strategies to address this neglect should include
the improvement of antivenom availability and the preclinical testing of antivenom efficacy [5,12].
A sine qua non requisite for an antivenom entering clinical trials (and eventually being approved
for clinical use) is the assessment of its ability to neutralize the most relevant toxic activities of the
venoms of the medically relevant snake species within the geographical range where the antivenom is
intended to be used [13,14]. To this end, simple experimental protocols have been developed [14,15].
An important progression to prevent the use of poor quality or ineffective antivenoms has been the
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launch by the WHO of a prequalification scheme of antivenoms for sub-Saharan Africa, a programme
also supported by the Global Snakebite Initiative and Médecins Sans Frontières [5,16–18].
The shortage of antivenoms can be in part counteracted by designing improved polyspecific
antivenoms with a broad neutralizing spectrum, but also by a more rational use of existing antivenoms,
i.e., through a systematic and detailed study of their paraspecificity. However, defining the venom
cross-reactivity landscape of an antivenom is not a trivial matter, given the well-documented occurrence
of venom variability in space (intra- and interpopulation) and time (ontogenetic) within and between
all taxonomic levels [19–22]. This circumstance prevents the use of phylogenetic distance as a
measure of venom compositional relatedness, even between closely-related species [23]. To assess
the paraspecificity of antivenoms to the level of species-specific toxins, a proteomics-based protocol
coined “antivenomics” was introduced in 2008, designed to quantify the extent of cross-reactivity
of an antivenom against homologous and heterologous venoms at toxin resolution [24]. The initial
protocol, which was based on the in-solution immunoprecipitation of antigen-antibody complexes
followed by the chromatographic quantification of the free antigen present in the supenatant, was only
suitable for whole IgG antivenoms. This “first generation” approach was subsequently re-designed
for the assessment of F(ab’)2 and Fab antivenoms [25]. Key to this update was the immobilization of
the antivenom molecules on a chromatographic matrix to generate an immunoaffinity column [25].
Among the most relevant advantages of this immunoaffinity-based “second-generation antivenomics”
approach, are (i) its ability to yield direct information on both the non-binding and bound toxins and
(ii) the smoother baseline of the surrogate reverse-phase chromatograms of the affinity column fractions.
These improvements allow better resolution and a more accurate quantification of an antivenom
immunorecognition profile than the original immunodepletion protocol. Here, this study reports on a
further update of the method that makes it possible to determine the binding capacity of antivenoms
for each of a venom’s toxins. In addition, this protocol, called “third generation antivenomics,” includes
the quantification of the fraction of antivenom molecules bearing immunoaffinity against venom toxins.
This platform has been applied for assessing the immunoreactivity of antivenom EchiTAb-Plus-ICP®
(which was used for developing the second generation antivenomics workflow) toward homologous
B. arietans venom toxins and its paraspecificity against the venom of N. melanoleuca.
2. Results and Discussion
2.1. Toxin-Resolved Immunocapturing Ability of EchiTAb-Plus-ICP® Antivenom towards Homologous Bitis
Arietans (Ghana) Venom
Polyclonal antivenoms have different affinities and number of antibodies against the different
toxins of a venom. The binding capacity of EchiTAb-Plus-ICP® toward the different toxins present in
the venom of B. arietans from Ghana was assessed by incubating identical affinity chromatographic
columns with increasing amounts of venom until saturation was reached. Comparison of the not
immunoretained fractions of a series of eight affinity columns incubated with 100–1500 µg of total
venom proteins (Figure 1) showed distinct concentration-dependent patterns of maximal binding for
different chromatographic peaks. The calculated venom concentration–dependent immunocapturing
capability of the antivenom for each of the chromatographic fractions separated as in panel a of Figure 1
are listed in Supplementary Materials Table S1, and graphically represented in Figure 2. Major PI
snake venom metalloproteinase (PI-SVMP) and serine proteinase toxins eluted, respectively, in peaks
26 and 15 (Figure 1, panel a) saturated their affinity binding sites at venom concentration of 300–500 µg.
All other venom toxins reached maximal binding at venom concentrations between 900–1200 µg.
The maximal binding capacity of the antivenom column was 348.1 µg of total venom proteins, which
corresponds to 43.5 mg of B. arietans venom proteins per gram of EchiTAb-Plus-ICP® IgG molecules.
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respectively. Panels b–i, not immunoretained venom fraction in 300 µL of immobilized (8 mg) 
EchiTAb-Plus-ICP® antivenom immunoaffinity columns incubated with increasing amounts (100–
1500 µg), respectively, of venom proteins. Panels j and k, not immunoretained and retained venom 
fractions in a mock column run in parallel to the immunoaffinity columns as matrix control; panel l, 
specificity control, venom proteins retained in a control IgG column. 
 
Figure 2. Graphical representation of the binding capacity of the different toxin classes of B. arietans 
(Ghana) venom in 300 µL of immobilized (8 mg) EchiTAb-Plus-ICP® antivenom immunoaffinity 
columns as a function of the amounts of incubated venom proteins (100–1500 µg). The maximal 
binding capacity of EchiTAb-Plus-ICP® for toxin “I”, defined as the ratio (µg toxin “i”/mg 
antivenom) that saturates the affinity column (Rsat“i”), was determined in a series of antivenomic 
experiments where a set of identical affinity columns are incubated with increasing amounts of 
venom, and plotting the amount of µg of toxin “i” immunoretained in the columns against the total 
amount of toxin“i”, (t“i”)TOT, contained in the incubated venom samples. (t“i”)TOT (in µg) = ((% of 
toxin“i” in the venom) × µg incubated venom)/100, and the relative abundance (%) of toxin “i” 
corresponds to the % of the total chromatographic area. 
Gutiérrez and co-workers [28] have reported an effective dose 50% (ED50, µL antivenom/mg 
venom which reduced by 50% the lethality induced in 18–20 g mice by 5 median lethal doses (LD50) 
Figure 1. Reverse-phase PLC profiles of 100 µg of B. arietans (Ghana) veno toxins (panel a).
Toxins eluting in the different chro atographic peaks were reported in [26,27]. DISI, disintegrin;
Kun, Kunitz-type inhibitor; PLA , phospholipase A ; SerPro, serine proteinase; CTL, C-type
lectin-like protein; PI- and PIII-SVMP, snake enom metalloproteinase of class PI and PIII, respectively.
Panels b–i, not immunoretained venom fraction in 300 µL of immobilized (8 mg) EchiTAb-Plus-ICP®
antivenom immunoaffinity columns incubated with increasing amounts (100–1500 µg), respectively, of
venom proteins. Panels j and k, not immunoretained and retained venom fractions in a mock column
run in parallel to the immunoaffinity columns as matrix control; panel l, specificity control, venom
proteins retained in a control IgG column.
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Figure 2. Graphical representation of the binding capacity of the different toxin classes of B. arietans
( hana) veno in 300 µL of immobilized (8 mg) EchiTAb-Plus-ICP® antiveno i unoaffinity
colu ns as a function of the a ounts of incubated veno proteins (100–1500 µg). The axi al
binding capacity of EchiTAb-Plus-ICP® for toxin “I”, defined as the ratio (µg toxin “i”/mg antiveno )
that saturates the affinity column (Rsat“i”), was determined in a series of antivenomic experiments
where a set of identical affinity columns are incubated with increasing amounts of venom, and plotting
the a ou t of µg of toxin “i” immunoretained in the columns against t t tal amount of toxin“i”,
(t“i”)TOT, contai ed in the incubated venom samples. (t“i”)TOT (in µg) = ((% of toxin“i” in the venom)
× µg incubated )/100, and the relative abundance (%) of toxin “i” corresponds to the % of the
total chromatographic area.
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Gutiérrez and co-workers [28] have reported an effective dose 50% (ED50, µL antivenom/mg
venom which reduced by 50% the lethality induced in 18–20 g mice by 5 median lethal doses (LD50)
of B. arietans (Nigeria) venom) for EchiTAb-Plus-ICP® of 181–312 µL. This figure corresponded to
a neutralization capacity of 66–114 mg venom proteins per gram of antivenom. In more recent
investigations, Segura et al. [29] and Sánchez et al. [30] reported, respectively, ED50s for the same
antivenom of 42.3–66.6 and 27.5–80 mg venom/g IgG. EchiTAb-Plus-ICP® was able to completely
prevent lethality at a higher dose, namely 667 µL antivenom/mg venom [29], at which 1 g of antivenom
would neutralized 31 mg of venom proteins. These data agree with those derived in this work for
the maximal venom proteins binding capacity of EchiTAb-Plus-ICP® antivenom. A combination of
experimental (in solution versus immobilized antivenom) and biological (geographic variability of
B. arietans venom [31]) particularities may account for the small differences noted.
Although a comparison of the levels of immune recognition gathered from antivenomics with the
in vivo neutralization capacity of an antivenom is not straightforward (since both experiments involve
radically different protocol, an immunocapturing capability of ~20–25% of total venom proteins
correlates with a good outcome in in vivo neutralization tests [32]. In this respect, the results shown
in Supplementary Materials Table S1 indicate that, with the sole exception of disintegrins and a
Kunitz-type serine proteinase inhibitor, the degree of immunodepletion of all other venom toxins
reached 55 to 93% at maximal binding conditions. The good correlation between third generation
antivenomics and in vivo neutralization assays highlights the complementarity of both approaches
to assess the preclinical efficacy of an antivenom to neutralize venom lethality [30]. In addition,
antivenomics has the unique ability of providing the grounds for rationalizing the homologous or
paraspecific efficacy of an antivenom, valuable knowledge for aiding in the design of immunogen
mixtures for generating antivenoms exhibiting improved therapeutic scope.
2.2. Toxin-Resolved Immunocapturing Ability of EchiTAb-Plus-ICP® Antivenom towards Heterologous Forest
Cobra (Naja melanoleuca, Ghana) Venom
The ability of EchiTAb-Plus-ICP® to immunocapture individual toxins of Ghanan N. melanoleuca
was assessed as described above for B. arietans. To this end, affinity columns containing 8 mg of
immobilized antivenom IgG molecules were challenged with 100–1200 µg of forest cobra venom
proteins. Antivenom IgGs failed to bind the three-finger toxin (3FTx) molecules eluted between
8–14 min across the entire range of venom concentrations tested (Supplementary Materials Table S2
and Figures 3 and 4). The other venom toxins were recognized by antivenom molecules, albeit
saturating their immunorecognition sites at different antivenom:venom ratios and exhibiting disparate
degrees of immunocapturing at maximal binding: 3FTxs eluting between 18–22 min and vespryn
showed immunoaffinity binding yields of 12–28%; cysteine-rich secretory proteins (CRISP), 26–56%;
phospholipases A2 (PLA2s), 28–63%; PIII-snake venom metalloproteinases (SVMPs), 31–68%; and
L-amino acid oxidase (LAO), 61–73%.
2.3. Toxicovenomics-Guided Toxin-Resolved Antivenomics Predictions
The maximal binding capacity of the 8 mg EchiTAb-Plus-ICP® antivenom column was 156.5 µg
of total venom proteins (Supplementary Materials Table S2). This figure corresponded to 19.6 mg
of N. melanoleuca venom proteins per gram of IgG molecules. Assuming that the degree of toxin
immunorecognition by an antivenom represents a measure of its capability to neutralize the venom’s
lethal activity, a 10 mL vial of EchiTAb-Plus-ICP® (40 mg IgG/mL; calculated ED50 for N. melanoleuca
(Uganda) = 0.66 mg/kg (95% confidence interval 0.49–0.92 mg/kg for 18–20 g mice) [33]), could
theoretically neutralize 8–16 LD50s. Native to the central and western parts of the African continent,
the forest cobra represents the largest true cobra (Naja) species [34]. It yields 0.5–1.1 g venom proteins
per milking [35]. Thus, 51–102 vials of EchiTAb-Plus-ICP® might be required to bind, and eventually
neutralize, such an amount of venom proteins. However, the antivenomics data highlight the
poor immunorecognition of venom 3FTxs, the most abundant (57% of the venom proteome) and
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lethal components of forest cobra venom. Most relevant, α-neurotoxins eluting between 8–14 min
comprise 24% of N. melanoleuca venom toxins, exhibit LD50s <0.2 µg/g mouse [33] and show no
affinity for EchiTAb-Plus-ICP® antibodies. This means that a bite injecting the whole venom load can
inoculate as much as 120–240 mg of 3FTxs toxins, quantities capable of killing 4–8 75 kg humans, and
against which the antivenom is not effective. Clearly, clinical studies are required to determine the
effectiveness of EchiTAb-Plus-ICP® against envenomings by N. melanoleuca. However, toxicovenomics
and toxin-resolved antivenomics evidence strongly suggest a poor outcome for this antivenom against
forest cobra envenomations.
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Figure 4. Graphical representation of the binding capacity of the different toxin classes of N. melanoleuca
(Ghana) venom in 300 µL of immobilized (8 mg) EchiTAb-Plus-ICP® antivenom immunoaffinity
columns as a function of the amounts of incubated venom proteins (100–1200 µg). The maximal
binding capacity of EchiTAb-Plus-ICP® for forest cobra venom toxins was calculated as described in
the legend of Figure 2.
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2.4. Quantification of Venom-Specific Antivenom Antibodies
In almost all existing antivenoms, antibodies toward non-venom antigens represent the most
abundant molecules. IgGs from normal and hyperimmune sera are indistinguishable chemically
and structurally, and quantification of the content of anti-toxin antibodies is seldom determined as
part of the preclinical evaluation of an antivenom. However, this parameter is relevant to compare
both the effectiveness of antivenoms with the same nominal venom specificity but manufactured
by different companies, and the binding capacity of the same antivenom toward homologous and
heterologous venoms. Estimation of the relative abundance of therapeutic molecules in an antivenom
preparation has been addressed through immunochemical methods, e.g., by determining the ratio
of potency (ED50 expressed as mg venom neutralized per mL antivenom) to total protein content
(mg/mL) [36]. The fraction of therapeutic molecules present in the antivenom preparation ([Abther])
can be calculated using the Equation (Abther) = (ED50/(Mave toxins))/((Ab)/MAb), where (Mave toxins)
is the average molecular mass of the venom toxins, (Ab) is the total protein concentration (mg/mL)
of the antivenom preparation, and MAb is the molecular mass of the active antivenom’s molecules
(158 kDa for IgG, 100 kDa for (F(ab’)2, 50 kDa for Fab). Here, analysis of size-exclusion HPLC (SEC)
elution profiles of increasing venom:antivenom ratio mixtures [37–40] have been applied to quantify
stable (EchiTAb-Plus-ICP® antibody-(B. arietans toxin)) complexes. SE-HPLC elution profiles are
mechanistically easy to interpret and mathematically modeled using dose-response functions based
on the law of mass action.
Figure 5 illustrates SEC elution profiles of reaction mixtures of a constant amount of antivenom
(300 µg) incubated with increasing amounts (12.75–306 µg) of B. arietans venom. The observed
profile changes were attributed to antivenom-venom complex formation, resulting in mass transfer
from zone 2 (Z2), where only venom protein elute, to zone 1 (Z1), where the elution of some high
molecular mass venom proteins, antivenom IgG molecules, and antigen-antibody complexes partially
overlap. To quantitate the fraction of the zone 1 area increase corresponding to the formation
of venom-antivenom complexes, it was necessary to subtract from each reaction profile the area
contributed by the free reactants. To this end calibration curves for free antivenom (AV) IgG and
venom (VE) alone were constructed and the amount of venom proteins bound by a constant amount
of antivenom at any venom:antivenom ratio was calculated by Equation: (Area AV-VE complexes) =
(area Z1 AV-VE chromatogram) − (area control AV) − (area control VE), where the areas of control AV
and control VE correspond to those of equal amounts used in the reaction mixture.
Using this approach, it was calculated that 1 gram (6.6 micromoles) of EchiTAb-Plus-ICP® IgGs
had maximal binding capacity of 51 mg (2 micromoles) B. arietans venom proteins. This value agrees
well with the quantification obtained by antivenomics in Section 2.1. Assuming that each IgG molecule
bound two molecules of target venom protein, we estimated that 15% of EchiTAb-Plus-ICP® antibody
molecules target B. arietans (Ghana) venom toxins. Taking into account that EchiTAb-Plus-ICP®
is a polyspecific antivenom and that B. arietans venom is only one of the three venoms used in
its generation [26], this figure is in agreement with the value, frequently quoted in the toxinology
community, of 10–40% of non-immunopurified animal antivenom antibodies being directed against
venom components [36,41,42].
Attempts to measure the amount of IgGs specific against N. melanoleuca toxins gave results not
significantly different from the control. This failure in the determination of stable immunocomplexes
may be attributed to a combination of low immunoreactivity and low affinity of EchiTAb-Plus® IgGs
against the toxins of the forest cobra venom, which was not included in the immunization mixture
used to generate the antivenom.
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Figure 5. Size-exclusion chromatographic approach used to quantify the fraction of EchiTAb-Plus-ICP®
IgG molecules toxin capable of forming stable complexes with B. arietans (Ghana) venom toxins.
Panel (A) displays SEC elution profiles of different amounts of B. arietans venom proteins used to
construct the calibration standard curve displayed in panel (B). Zone 1 includes venom components
that overlap with antivenom IgGs, and antigen-antibody complexes. Zone 2 is the region of the
chromatogram where free venom proteins are eluted. Panel (C) displays superposition of SEC
profiles of reaction mixtures comprising a constant amount of antivenom (300 µg) incubated with
increasing amounts (12.75–306 µg) of B. arietans venom proteins. Increment of zone 1 area was
attributed to antivenom-venom complex formation. and calculated using the Equation (Area venom
complexed with antivenom IgG) = (total area zone-1) − (area 300µg IgG) − (area zone-1 control
venom curve). Panel (D) displays the calculated area attributed to antivenom-venom complexes as
a function of the amount of venom in the reaction mixture. Blue line, sum of the zone 1 areas of
the standard curves of venom and antivenom; Magenta line, area of zone 1 of the chromatographic
profiles of venom-antivenom mixtures. The maximal increment in area was then used to calculate,
using the calibration curve plotted in (B), the maximal binding capacity of a defined amount of
EchiTAb-Plus-ICP® antivenom.
3. Concluding Remarks and Perspectives
Antivenomics is translational venomics applied for the functional characterization of antivenoms.
In addition to the physicochemical characteristics of the immune molecules (e.g., homogeneity and
purity of IgG, F(ab’)2, or Fab), relevant functional parameters that should be determined in the
preclinical stage of an antivenom include (i) its efficacy to neutralize the toxic effects of the target
venom; (ii) toxin-specificity and paraspecificty; and (iii) the quantification of the fraction of therapeutic
molecules. Analysis of the neutralizing activity of a venom’s toxic effects, including lethality, in vivo or
ex vivo systems are recommended [15,18], while for the molecular aspects of the preclinical assessment
(immunoreactivity profiling and quantification of venom-specific molecules), in vitro protocols have
been developed [25,40]. The testing of antivenoms on animals raises important ethical considerations,
and the WHO recommends the systematic second-generation antivenomics quality control for each
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new batch of an antivenom before animal experiments are undertaken [18]. As pinpointed in the review
by Gutiérrez et al. of this issue [15], in order to reduce the use and suffering of experimental animals,
the philosophy of the 3Rs (i.e., Reduce, Refine, and Replace animal tests) needs to be actively promoted
in the field of antivenoms, including the systematic use of analgesics and the development of novel
in vitro assays in substitution of in vivo tests. To fulfill these recommendations, the second generation
antivenomics protocol has been updated to include the determination of the maximal binding capacity
of the immunoaffinity column for the different toxins of a venom and the quantification of the fraction
of toxin-specific antibodies present in the antivenom. SE-HPLC elution profile analysis has been
previously used as a rapid means of separating and quantifying stable antibody (Ab)-antigen (Ag)
complexes from unbound reactants [38–40]. SE-HPLC has the advantage over other chromatographic
methods in that it can be performed under conditions that preserve the native structure and binding
characteristics of venoms and antivenoms. This improvement in the analytical capabilities of the
protocol termed “third generation (3G) antivenomics” allows a more detailed functional comparison
of nominally identical antivenoms in terms of immunological profile. As shown in the case of
N. melanoleuca, the interpretation of 3G antivenomics in the context of the venom toxicovenomic
profile could eventually replace in vivo tests, with the consequent reduction of the use of animals in
the evaluation of antivenom protection against venom-induced lethality.
4. Materials and Methods
4.1. Venoms and Antivenom
Venom from the puff adder, Bitis arietans, from Ghana was generously provided by
Dr. Robert A. Harrison (Liverpool School of Tropical Medicine, Liverpool, UK), and its toxin composition
has been previously characterized [26,27]. Venom from the forest (or black) cobra, Naja melanoleuca,
from Ghana was purchased from Latoxan (Valence, France). Proteomic characterization of the venom
of N. melanoleuca from Uganda has been reported [33], and that of the same Ghanan species will be
reported elsewhere. Antivenom EchiTAb-Plus-ICP© (batch n◦: 5620715PALQ; manufactured: July 2015;
expiring date: July 2018) was generously provided by Prof. José María Gutiérrez (Instituto Clodomiro
Picado, Universidad de Costa Rica, San José, Costa Rica). Details of its production and immunological
profile have been reported [28–31,43–46].
4.2. Antivenomics
The EchiTAb-Plus-ICP® antivenom (Instituto Clodomiro Picado, Universidad de Costa Rica,
San José, Costa Rica) was dialysed against MilliQ® water, lyophilised, and reconstituted in 0.2 M
NaHCO3, 0.5 M NaCl, pH 8.3 (coupling buffer). Antivenom affinity columns were prepared in batch.
6 mL of CNBr-activated Sepharose™ 4B matrix (Ge Healthcare, Buckinghamshire, UK) packed in
a ABT column (Agarose Bead Technologies, Torrejón de Ardoz, Madrid, Spain) and washed with
10 matrix volumes of cold 1 mM HCl, followed by two matrix volumes of coupling buffer to adjust the
pH of the column to 7.0–8.0. CNBr-activated instead of N-hydroxysuccinimide (NHS)-activated matrix
was employed because NHS released during the coupling procedure absorbs strongly at 280 nm, thus
interfering with the measurement of the concentration of antibodies remaining in the supernatant
of the coupling solution. The concentrations of the antivenom stock solutions were determined
spectrophotometrically using an extinction coefficient for a 1 mg/mL concentration (ε0.1%) at 280 nm of
1.36 (mg/mL) × cm−1 [47]. 200 mg of EchiTAb-Plus-ICP® antivenom were dissolved in the 2× matrix
volume of coupling buffer and incubated with the 6 mL matrix column for 4 h at room temperature.
Antivenom coupling yield, estimated measuring A280 before and after incubation with the matrix and
using the Beer-Lambert Law, was 26.7 mg/mL. After the coupling, remaining active groups were
blocked with 12mL of 0.1 M Tris-HCl, pH 8.5 at room temperature for 4 h. Seven affinity columns
containing 300 µL of immobilized (8 mg) EchiTAb-Plus-ICP® antivenom were alternately washed with
three matrix volumes of 0.1 M acetate containing 0.5 M NaCl, pH 4.0–5.0, and three matrix volumes of
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0.1 M Tris-HCl, pH 8.5, repeated six times. The columns were then equilibrated with five volumes of
working buffer (PBS, 20 mM phosphate buffer, 135 mM NaCl, pH 7.4) and incubated with increasing
amounts (100–1200 µg total venom proteins) of N. melanoleuca from Ghana dissolved in 1/2 matrix
volume of PBS, and incubated for 1 h at 25◦C using an orbital shaker. Another set of eight affinity
columns were incubated with increasing amounts (100–1500 µg total proteins) of B. arietans venom
from Ghana dissolved in 1/2 matrix volume of PBS, and incubated for 1 h at 25◦C using an orbital
shaker. As specificity controls, columns of 300 µL of CNBr-activated Sepharose™ 4B matrix, without
(mock) or with 8 mg of immobilized control horse IgGs, were incubated with venom and developed in
parallel to the immunoaffinity columns.
The non-retained fractions of columns incubated with 100-300 µg, 500-700 µg, 900 µg, 1200 µg,
and 1500 µg of venom were recovered with 5×, 10×, 15×, 20×, and 25× matrix volumen of PBS,
respectively. Sintiprungat et al. [48] have recently reported that the choice of eluting buffer can
significantly alter the binding of the proteins to the matrix and consequently the conclusions drawn
from antivenomics studies. In this study, the following elution conditions, alone or combined, were
compared: 0.1 M glycine-HCl, pH 2.7; 0.1 M glycine, pH 10.0; 0.1 M glycine-HCl, pH 2.7, including
2M NaCl; 0.1% trifluoroacetic acid (TFA) in 30% acetonitrile (ACN), followed by 0.1% TFA in 70% ACN;
3M sodium thiocyanate (NaSCN > 99.99%) (Sigma-Aldrich Quimica, Tres Cantos, Madrid, Spain); and
0.1 M glycine-HCl, pH 2.7 followed by 3M sodium thiocyanate. Eluates were collected in fractions
of 1/2 column volume, brought to neutral pH and/or desalted, concentrated by Speed-Vac (Savant™,
Thermo Scientific Inc., West Palm Beach, FL, USA), and analyzed by SDS-PAGE and reverse-phase
HPLC (as below). Best results were obtained with 0.1M glycine-HCl, pH 2.7. Therefore, in all the
experiments described in this work, the immunocaptured proteins were eluted with this buffer, the
eluates brought to neutral pH with 1M Tris-HCl, pH 9.0, and those fractions containing more than
90-95% of the eluted proteins were pooled for further analysis.
To avoid saturation of the downstream reverse-phase chromatographic analysis, a fraction
(1/x, x = 1, 2, 3, 4, and 5 of the non-retained and the immunocaptured venom fractions recovered,
respectively, with 5×, 10×, 15×, 20×, and 25× matrix volumen) were concentrated in a Savant™
SpeedVac™ vacuum system (ThermoFisher Scientific, Waltham, MA, USA) to 40 µL, and fractionated
by reverse-phase HPLC using an Agilent LC 1100 High Pressure Gradient System (Santa Clara, CA,
USA) equipped with a Discovery® BIO Wide Pore C18 (15 cm × 2.1 mm, 3 µm particle size, 300 Å pore
size) column (Supelco Sigma-Aldrich, Bellefonte, PA, USA) and a DAD detector (Agilent Technologies,
Santa Clara, CA, USA). The column was developed at a flow rate of 0.4 mL/min with a linear gradient
of 0.1% TFA in MilliQ® water (Merck-Millipore, Darmstadt, Germany) (solution A) and 0.1% TFA
in acetonitrile (solution B), isocratic (5% B) for 1 min, followed by 5–25% B for 5 min, 25–45% B
for 35 min, and 45–70% B for 5 min. Eluate was monitored at 215 nm with a reference wavelength
of 400 nm. The fraction of non-immunocaptured molecules was estimated as the relative ratio of
the chromatographic areas of the toxin recovered in the non-retained (NR) and retained (R) affinity
chromatography fractions using the Equation % NRi = 100 − [(Ri/(Ri + NRi)) × 100], where Ri
corresponds to the area of the same protein “i” in the chromatogram of the fraction retained and eluted
from the affinity column. However, for some toxins that were poorly recovered in the column-retained
fraction owing to the high affinity of the binding, the percentage of non-immunocaptured toxin“i”
(% NRtoxin“i”) was calculated as the ratio between the chromatographic areas of the same peak recovered
in the non-retained fraction (NRtoxin“i”) and in the injected crude reference venom (Vtoxin“i”), using the
Equation %NRtoxin“i” = (NRtoxin“i”/Vtoxin“i”) × 100.
4.3. Quantification of Antivenom-Toxin Complexes by Size-Exclusion Chromatography
Calibration curves were constructed plotting the chromatographic area as a function of increasing
amounts of EchiTAb-Plus-ICP® antivenom (50–750 µg) and total venom proteins of B. arietans (12.75,
25.5, 51, 153, 306 µg). To quantify the abundance of toxin-specific IgG molecules in EchiTAb-Plus-ICP®
antivenom, constant amounts of 300 µg of antivenom were incubated with the same amounts B. arietans
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total venom proteins used to construct the calibration curves in 50µL of 0.1 M ammonium acetate, pH 6.9,
for 1h at 37 ◦C. Assuming average molecular masses of 25 kDa for B. arietans toxins, these mixtures
correspond to venom:antivenom molar ratios of 0.33:1, 0.5:1, 1:1, 3:1, 6:1. Venom-antivenom mixtures
were fractionated by size-exclusion chromatography (SEC) using an ETTAN-LC chromatograph
(GE Healthcare, Buckinghamshire, UK) and a Bio-Sil SEC 250 (300 × 7.8 mm) column (Bio-Rad
Laboratories, Inc., Hercules, CA, USA) equilibrated in the same buffer and calibrated with a mixture
of dextran blue (>2 MDa), β-amilase (224 kDa), BSA (66.3 kDa), carbonic anhydrase (29 kDa) and
ATP (507 Da). The flow rate was set to 0.7 mL/min, the eluate was monitored at 215 nm and the
chromatographic fractions, collected manually, were analyzed for the presence of venom proteins by
RP-HPLC using the chromatographic conditions described in Section 4.2.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/9/5/158/s1,
Table S1: Total and concentration-dependent immunoretained B. arietans (Ghana) venom proteins by
EchiTAb-Plus-ICP® antivenom affinity column, Table S2: Total and concentration-dependent immunoretained
N. melanoleuca (Ghana) venom proteins by EchiTAb-Plus-ICP® antivenom affinity column.
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